Phase 3
N=99
Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
COPD · COPD Exacerbation · COPD Exacerbation Acute · Pollution Related Respiratory Disorder · Pollution; Exposure
Bottom Line
View on ClinicalTrials.gov: NCT03984188 ↗Enrolled (actual)
99
Serious AEs
8.1%
Results posted
Oct 2024
Primary outcome: Primary: Change in St. George Respiratory Questionnaire (SGRQ) Scores — 39.02; 45.06 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Theophylline ER (Drug); Placebo oral tablet (Drug); Standard of Care Treatment (Other)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- University of Miami
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in St. George Respiratory Questionnaire (SGRQ) Scores |
37.86; 44.45 | — |
| SECONDARY Change in Forced Expiratory Volume in One Second (FEV1) |
1.40; 1.40 | — |
| SECONDARY Change in Forced Vital Capacity (FVC) |
2.51; 2.52 | — |
| SECONDARY Change in Forced Vital Capacity (FVC) |
2.51; 2.52 | — |
| SECONDARY Change in St. George Respiratory Questionnaire (SGRQ) Scores |
37.86; 44.45 | — |
| SECONDARY Change in Forced Expiratory Volume in One Second (FEV1) |
1.40; 1.40 | — |
Summary
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, and over 90% of COPD-related deaths occurring in low- and middle-income countries (LMICs). Household air pollution (HAP) - from burning solid fuels such as wood, dung, agricultural crop waste, and coal for energy - is the primary risk factor for COPD in these settings. Biomass-related COPD has a distinct histopathology, phenotype and inflammatory profile when compared to tobacco mediated COPD. Despite the high global burden of biomass-related disease, little is known about the effectiveness of pharmacotherapies for biomass-related COPD; to date, no clinical trials have focused specifically on treatment of biomass-related COPD. This study proposes to assess the health impact of biomass-related COPD and test the effectiveness of low dose theophylline compared to standard therapy among adults with biomass-related COPD in Uganda with the aim to assess whether low-dose theophylline improves respiratory symptoms, decreases the inflammatory profile of serum biomarkers and whether administration attenuates the effect of HAP on lung function. The study additionally aims to assess whether low-dose theophylline is a cost-effective intervention based on the incremental cost-effectiveness ratio and a range of willingness to pay thresholds.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 40 years
- Full-time resident of study area
- Post-bronchodilator FEV1/FVC < the lower limit of normal of the Global Lung Initiative Mixed Ethnic reference population
- Grade B-D COPD
- Daily biomass exposure
Exclusion Criteria
- Plans to move within one year
- Uncontrolled hypertension
- Pregnancy (assessed by urine pregnancy test among women of childbearing age/menstrual history)
- Current use of chronic respiratory medications (Long acting Beta 2 Antagonists (LABA), Long-acting muscarinic antagonist (LAMA), inhaled corticosteroid (ICS))
- History of post-treatment pulmonary tuberculosis
- ≥10 pack year tobacco smoking history
- Known intolerance or contraindication to theophylline.
Data sourced from ClinicalTrials.gov (NCT03984188). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.